<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03278691</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 1072359</org_study_id>
    <nct_id>NCT03278691</nct_id>
  </id_info>
  <brief_title>Ketorolac on Posterior Thoracolumbar Spinal Fusions</brief_title>
  <official_title>The Effect of Ketorolac on Posterior Thoracolumbar Spinal Fusions: a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascension St John Providence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascension St John Providence</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine is low-dose ketorolac use in the early post-operative period (within 48 hours)
      provides adequate analgesia without long term adverse effect on spinal fusion rates when
      compared to post-operative analgesia without the use of NSAIDs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Anticipated">August 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion Construct X-Ray</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Each fusion level will be evaluated individually and as part of the complete fusion construct. Fusion will be evaluated by blinded independent neuroradiologists using XR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fusion Construct X-Ray</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>Each fusion level will be evaluated individually and as part of the complete fusion construct. Fusion will be evaluated by blinded independent neuroradiologists using XR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) for pain</measure>
    <time_frame>Every 8 hours x 48 hours postoperatively</time_frame>
    <description>Patient will be given the VAS on the source document in order to draw on the scale
Blinded investigators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay (LOS)</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>-Measured in days (24 hours)
â€¢ Automatic data capture on discharge by the hospital EMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - long term</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>Short Form (SF) 12
We will administer validated scales, Short form (SF)12
Face-to -face interview during clinic visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine equivalent doses</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>-Non-study narcotics taken by patients on the floor are converted to morphine equivalent doses
Morphine equivalent doses are compared between the two groups daily for the first 48h
Data extracted from hospital EMR on discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications/Adverse events</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>-Ketorolac-related short term in-hospital complications: GI ulceration and bleeding, GI perforation, PO bleeding, acute renal failure, anaphylactic/anaphylactoid reactions, liver failure
Collected by investigators daily during round
Document on the source document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - long term</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>Oswestry Disability Index (ODI)
We will administer validated scales (ODI)
Face-to -face interview during clinic visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - long term</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>We will administer validated scales, Visual Analog Scale (VAS)
Face-to -face interview during clinic visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Thoracolumbar Spinal Fusions</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Saline 1 ml IV Q6H</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketorolac 15 mg (15mg/ml) IV Q6H</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>1 ml saline IV Q6H</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>15 mg (15 mg/ml) IV Q6H</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years of age

          -  Elective thoracolumbar posterior lumbar instrumented interbody fusion

          -  Minimally invasive spine surgery (MIS)

          -  3 or fewer levels

          -  Bone Morphogenetic Protein (BMP) use in interbody fusion (1.05mg/level or less)

          -  Consent to study participation

        Exclusion Criteria:

          -  Active tobacco smoker or history of tobacco smoking in the past 6 weeks

          -  Previous history of surgery at operative level(s)

          -  History of chronic inflammatory/rheumatological condition

          -  History of systemic steroid use in the past 3 months

          -  Auto/Workers' compensation patients

          -  Traumatic pathology at the operative levels

          -  Infection at the operative levels

          -  Tumor at the operative levels

          -  Major psychiatric illness as diagnosed by psychiatrists and on major anti-
             psychotic/depressants

          -  Patients on chemotherapeutic agents in the last 6 months

          -  Patients who has a history of allergy to Ketorolac

          -  Patients with a history of chemical addiction requiring professional rehabilitation
             and/or assistance

          -  Patients with current creatinine &gt; 1.5mg/dl

          -  Patients with history of coagulopathy

          -  Patients with history of hepatic impairment

          -  Patients with uncontrolled cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Claus, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence-Providence Park Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chad Claus, DO</last_name>
    <phone>702-493-7856</phone>
    <email>chadfclaus@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence-Providence Park, Southfield</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Williams, MBA, MPH</last_name>
      <phone>248-849-5326</phone>
      <email>Frances.Williams3@ascension.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

